Evidence boundary
Current research does not define a normal TB-500 site reaction
TB-500 is commonly used as a name for a synthetic fragment related to thymosin beta-4, but product terminology is inconsistent and human safety evidence remains limited. ClinicalTrials.gov lists NCT07487363 as a recruiting industry-sponsored Phase 1/2 study of TB-500, identified as the thymosin beta-4 17–23 fragment, in an estimated 80 adults with stable atherosclerotic cardiovascular disease. Treatment-emergent and serious adverse events are primary outcomes, but the record has no results posted. The study cannot yet provide a patient-specific reaction rate, expected redness diameter, normal lump, or recovery countdown for a compounded injection.
- Do not turn a recruiting trial, full-length thymosin beta-4 study, animal finding, seller testimonial, or clinic symptom list into a percentage for local TB-500 reactions.
- Timing after an injection creates a useful clinical timeline, but it does not identify whether the cause is the fragment, an excipient, irritation, bruising, allergy, infection, storage failure, supplies, or another skin problem.
- A controlled investigational product and protocol should not be assumed equivalent to a patient-specific compounded preparation, an unidentified blend, or a research-market vial.
Describe the site precisely
Redness, warmth, itching, pain, swelling, and drainage are not interchangeable
A local reaction should be described rather than labeled “normal,” “allergic,” or “infected” from a photo alone. Record pain or tenderness, itching, bruising, firmness, warmth, the direction of change, drainage, red streaking, fever, chills, skin-color change, and symptoms away from the site. MedlinePlus notes that cellulitis may involve painful, red, tender skin with swelling or fever and can require medical evaluation and antibiotics. An online guide cannot diagnose cellulitis, an abscess, a serious allergy, or tissue injury, and the absence of fever does not clear a worsening site.
- Report whether the border is spreading, pain is escalating, a firm area is enlarging, movement is affected, drainage appears, or the site recurs after repeated exposure.
- Share diabetes, immune suppression, circulation problems, skin disease, prior cellulitis or abscess, adhesive or antiseptic allergy, pregnancy, bleeding risk, and current medicines because these can change assessment.
- A persistent, recurrent, expanding, unusually painful, draining, or treatment-limiting reaction deserves clinician review even if a seller calls it routine.
Identity and pharmacy review
TB-500, thymosin beta-4, formulations, refills, and supplies can differ
Full-length thymosin beta-4 is a 43-amino-acid peptide, while analytical literature has identified a tested TB-500 product as an acetylated seven-amino-acid fragment corresponding to residues 17–23. Sellers may use TB-500, TB4, thymosin beta-4, fragment, free-base, acetate, and blend terms inconsistently. TB-500 has no FDA-approved finished-drug label, and a patient-specific compounded preparation is not an FDA-approved finished drug product. Sequence, form, concentration, excipients, container, sterility controls, storage, beyond-use date, dispensing source, and supplies can change the safety question.
- Bring the exact ingredient or sequence when known, form, concentration, excipients, route, prescriber, dispensing pharmacy, lot, beyond-use date, shipment condition, storage history, and supply source to the review.
- Report a damaged seal, unclear label, visible particles or discoloration, temperature problem, unexpected packaging change, or symptoms that began with a new lot, refill, concentration, base, or set of supplies.
- Research-use vials, no-prescription checkout, hidden pharmacy identity, copied injection maps, unsupported “sterile” claims, and sellers that dismiss reactions without clinical review are red flags.
Do not improvise treatment
A seller protocol cannot decide the next dose or treat the site
The next decision depends on severity, spread, allergy and infection features, the exact product, medical history, other exposures, and an examination when needed. Reinjecting, changing the amount or route, using leftover antibiotics, adding an antihistamine, applying prescription creams, squeezing or draining a lump, or covering a worsening site can delay diagnosis or add allergy, interaction, sedation, masking, or tissue-injury risk. The responsible clinician should decide whether the product is held, whether the site needs local assessment, and whether the pharmacy or an adverse-event channel should be contacted.
- Do not reuse or share single-use supplies, use research material as medication, or continue a product with a damaged seal, unclear label, visible change, or questionable storage.
- Do not borrow antibiotics, steroid creams, antihistamines, pain medicines, or “peptide reaction” remedies without checking allergy, pregnancy, sedation, bleeding, kidney, liver, and interaction context.
- Photos and product details can support review, but remote messaging should not delay urgent local care when redness spreads, pain escalates, drainage or fever appears, or skin breaks down.
Escalation and regulatory context
Separate follow-up from infection or anaphylaxis emergencies
MedlinePlus describes anaphylaxis as a severe whole-body allergic reaction that can develop quickly and involve hives, swelling, wheezing, breathing difficulty, dizziness, or loss of consciousness. Those findings are not a routine injection-site reaction. FDA’s July 23–24, 2026 Pharmacy Compounding Advisory Committee discussion of TB-500 free base and acetate was part of a section 503A bulks-list process; the meeting did not itself create FDA approval, a finished-drug label, a local-reaction rate, or patient dosing guidance. Verify current status through official records and the responsible clinician and pharmacy rather than a seller headline.
- Call emergency services for trouble breathing, throat tightness, facial or tongue swelling, wheezing, fainting, confusion, or rapidly developing widespread hives or swelling.
- Seek prompt local assessment for rapidly expanding redness or swelling, severe or escalating pain, pus or drainage, red streaks, fever or chills, blistering, darkening, numbness, or skin breakdown.
- Contact the prescriber for persistent, recurrent, enlarging, or treatment-limiting local symptoms and before another dose, refill, route, formulation, or pharmacy decision.